Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Edwards Lifesciences Corp. for $13.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Balance Sheet: Assets
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Edwards Lifesciences Corp., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Cash and cash equivalents
Short-term investments
Accounts receivable, net of allowances
Other receivables
Accounts and other receivables, net of allowances (legacy)
Inventories
Deferred income taxes
Prepaid expenses
Other current assets
Current assets
Long-term accounts receivable, net of allowances
Long-term investments
Property, plant, and equipment, net
Operating lease right-of-use assets
Goodwill
Other intangible assets, net
Deferred income taxes
Other assets
Long-term assets
Total assets

Based on: 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-29), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-29).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Edwards Lifesciences Corp.’s current assets increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Property, plant, and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Edwards Lifesciences Corp.’s property, plant, and equipment, net increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Edwards Lifesciences Corp.’s long-term assets increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Edwards Lifesciences Corp.’s total assets increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Edwards Lifesciences Corp.’s cash and cash equivalents increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Edwards Lifesciences Corp.’s short-term investments decreased from Q1 2020 to Q2 2020 but then slightly increased from Q2 2020 to Q3 2020.
Accounts receivable, net of allowances Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
Accounts and other receivables, net of allowances (legacy) The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. Edwards Lifesciences Corp.’s accounts and other receivables, net of allowances (legacy) decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Edwards Lifesciences Corp.’s inventories increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.